secwatch / observer
GNVR Genvor Inc
CIK 0001792941 18 ready 8-Ks latest June 22, 2026, 4:15 PM ET RSS · JSON
Activity: NORMAL 1 filings / 30d vs 0 baseline
Ready 8-Ks 18
Latest filing June 22, 2026, 4:15 PM ET
Top materiality 0.90
Event mix leadership ×7 · other_material ×6 · other ×3
Sentiment 0 pos · 5 neg · 13 neu
Executive change recent →
SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for GNVR

Executive changes

Appointed

Donald Kalkofen

Chief Financial Officer
GNVR · Genvor Inc
Effective
2026-05-18
Filed
May 21, 2026, 4:15 PM ET
appointed Donald Kalkofen as the Company’s Chief Financial Officer effective as of May 18, 2026.
Appointed

Chad Pawlak, Sr.

Director
GNVR · Genvor Inc
Effective
2024-11-12
Filed
November 13, 2024, 6:59 PM ET
On November 12, 2024, Chad Pawlak, Sr. was elected as a Board of Directors of Genvor Incorporated (the “Company”).
Departed

Judith S. Miller

Director
GNVR · Genvor Inc
Effective
2024-08-07
Filed
October 22, 2024, 7:59 PM ET
On August 7, 2024, Judith S. Miller resigned as a member of the Board of Directors of Genvor Incorporated (the “Company”).
Departed (interim)

Judith S. Miller

Interim Chief Financial Officer and Chief Business Officer
GNVR · Genvor Inc
Effective
2024-05-29
Filed
June 3, 2024, 7:59 PM ET
On May 29, 2024, Judith S. Miller was terminated as Interim Chief Financial Officer and Chief Business Officer of the Company.
Role change (interim)

Judith S. Miller

member of the Board, Chief Business Officer, and Interim Chief Financial Officer
GNVR · Genvor Inc
Effective
2024-01-17
Successor
Chad Pawlak
Filed
January 23, 2024, 6:59 PM ET
Judith S. Miller resigned as the Company’s Interim Chief Executive Officer and was appointed as a member of the Company’s Board of Directors (the “ Board ”), as the Chief Business Officer of the Company, and as the Interim Chief Financial Officer of the Company
Appointed

Dr. Jesse Jaynes

Chief Scientific Officer
GNVR · Genvor Inc
Effective
2024-01-17
Filed
January 23, 2024, 6:59 PM ET
Dr. Jesse Jaynes was appointed as the Chief Scientific Officer of the Company
Role change

Dr. Clayton Yates

scientific advisor
GNVR · Genvor Inc
Effective
2024-01-17
Successor
Dr. Jesse Jaynes
Filed
January 23, 2024, 6:59 PM ET
Dr. Clayton Yates resigned as Chief Scientific Officer of the Company and was appointed as a scientific advisor for the Company
Appointed

Chad Pawlak

Chief Executive Officer
GNVR · Genvor Inc
Effective
2024-01-17
Filed
January 23, 2024, 6:59 PM ET
Chad Pawlak was appointed as Chief Executive Officer of Genvor Incorporated
Appointed (interim)

Judith S. Miller

Interim Chief Executive Officer
GNVR · Genvor Inc
Effective
2023-06-20
Filed
July 6, 2023, 7:59 PM ET
Judith S. Miller was appointed as Interim Chief Executive Officer of the Company
Departed

Bradley White

Other Named Officer
GNVR · Genvor Inc
Effective
2023-06-20
Successor
Judith S. Miller
Filed
July 6, 2023, 7:59 PM ET
On June 20, 2023, Bradley White was terminated as an officer of Genvor Incorporated

Materiality & sentiment trend

Max materiality 0.90 · Median 0.53 · Most common event leadership

0 positive 5 negative 13 neutral

source · GNVR on sec.gov